|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer显示文摘 | Yoon-Koo Kang Kei Muro Min-Hee Ryu Hirofumi Yasui Tomohiro Nishina Baek-Yeol Ryoo Yukimasa Kamiya Shiro Akinaga Narikazu Boku | 2014 | Investigational New Drugs2014，，2： | 5 |
| 2 | Study protocol of the Asian XELIRI ProjecT(AXEPT):a multinational,randomized,non-inferiority,phase Ⅲ trial of second-line chemotherapy for metastatic colorectal cancer, comparing the eicacy and safety of XELIRI with or without bevacizumab versus FOLFIRI w显示文摘Background: Capecitabine and irinotecan combination therapy(XELIRI) has been examined at various dose levels to treat metastatic colorectal cancer(m CRC). Recently, in the Association of Medical Oncology of the German Cancer Society(AIO) 0604 trial, tri?weekly XELIRI plus bevacizumab, with reduced doses of irinotecan(200 mg/m^2 on day 1) and capecitabine(1600 mg/m^2 on days 1–14), repeated every 3 weeks, has shown favorable tolerability and eicacy which were comparable to those of capecitabine and oxaliplatin(XELOX) plus bevacizumab. The doses of capecit?abine and irinotecan in the AIO trial are considered optimal. In a phase I/II study, XELIRI plus bevacizumab(BIX) as second?line chemotherapy was well tolerated and had promising eicacy in Japanese patients.Methods: The Asian XELIRI Projec T(AXEPT) is an East Asian collaborative, open?labelled, randomized, phase Ⅲ clinical trial which was designed to demonstrate the non?inferiority of XELIRI with or without bevacizumab versus standard FOLFIRI(5?fluorouracil, leucovorin, and irinotecan combination) with or without bevacizumab as second?line chemo?therapy for patients with m CRC. Patients with 20 years of age or older, histologically conirmed m CRC, Eastern Coop?erative Oncology Group performance status 0–2, adequate organ function, and disease progression or intolerance of the irst?line regimen will be eligible. Patients will be randomized(1:1) to receive standard FOLFIRI with or with?out bevacizumab(5 mg/kg on day 1), repeated every 2 weeks(FOLIRI arm) or XELIRI with or without bevacizumab(7.5 mg/kg on day 1), repeated every 3 weeks(XELIRI arm). A total of 464 events were estimated as necessary to show non?inferiority with a power of 80% at a one?sided α of 0.025, requiring a target sample size of 600 patients. The 95% conidence interval(CI) upper limit of the hazard ratio was pre?speciied as less than 1.3.Conclusion: The Asian XELIRI Projec T is a multinational phase III trial being conducted to provide evidence for XELIRI with or without bevacizumab as a second?line treatment option of mCRC. | Masahito Kotaka Ruihua Xu Kei Muro Young Suk Park Satoshi Morita Satoru Iwasa Hiroyuki Uetake Tomohiro Nishina Hiroaki Nozawa Hiroshi Matsumoto Kentaro Yamazaki Sae-Won Han Wei Wang Joong Bae Ahn Yanhong Deng Sang-Hee Cho Yi Ba Keun-Wook Lee Tao Zhang Taroh Satoh Marc E.Buyse Baek-Yeol Ryoo Lin Shen Junichi Sakamoto Tae Won Kim | 2016 | Chinese Journal of Cancer2016，35，12： | 3 |
| 3 | Phase II trial of nanoparticle albumin‐bound paclitaxel as second‐line chemotherapy for unresectable or recurrent gastric cancer显示文摘 | Yasutsuna Sasaki Tomohiro Nishina Hirofumi Yasui Masahiro Goto Kei Muro Akihito Tsuji Wasaburo Koizumi Yasushi Toh Takuo Hara Yoshinori Miyata | 2014 | Cancer Sci2014，，7： | 2 |
| 4 | A case of small undifferentiated intramucosal gastric cancer with lymph node metastasis显示文摘 | Junichirou Nasu Shinichiro Hori Akinori Asagi Tomohiro Nishina Yoshio Ikeda Masahito Tanimizu Haruo Iguchi Kenjiro Aogi Akira Kurita Rieko Nishimura | 2010 | Gastric Cancer2010，，4： | 1 |
| 5 | Granular cell tumor occurring in the sigmoid colon treated by endoscopic mucosal resection using a transparent cap (EMR-C)显示文摘 | Shinji Endo Shoji Hirasaki Toshihiko Doi Hisashi Endo Tomohiro Nishina Toshikazu Moriwaki Masahito Nakauchi Toshikazu Masumoto Masahito Tanimizu Ichinosuke Hyodo | 2003 | Journal of Gastroenterology2003，，4： | 1 |
| 6 | Genotype‐directed, dose‐finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms显示文摘 | Taroh Satoh Takashi Ura Yasuhide Yamada Kentaro Yamazaki Toshimasa Tsujinaka Masaki Munakata Tomohiro Nishina Shu Okamura Taito Esaki Yasutsuna Sasaki Wasaburo Koizumi Yoshihiro Kakeji Naoki Ishizuka Ichinosuke Hyodo Yuh Sakata | 2011 | Cancer Science2011，，10： | 1 |
| 7 | Granular cell tumor occurring in the sigmoid colon treated by endoscopic mucosal resection using a transparent cap (EMR-C)显示文摘 | Shinji Endo Shoji Hirasaki Toshihiko Doi Hisashi Endo Tomohiro Nishina Toshikazu Moriwaki Masahito Nakauchi Toshikazu Masumoto Masahito Tanimizu Ichinosuke Hyodo | 2003 | Journal of Gastroenterology2003，，4： | 1 |
| 8 | Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)显示文摘 | Kei Muro Narikazu Boku Yasuhiro Shimada Akihito Tsuji Shinichi Sameshima Hideo Baba Taroh Satoh Tadamichi Denda Kenji Ina Tomohiro Nishina Kensei Yamaguchi Hiroya Takiuchi Taito Esaki Shinya Tokunaga Hiroyuki Kuwano Yoshito Komatsu Masahiko Watanabe Ichin | 2010 | Lancet Oncology2010，，9： | 1 |
| 9 | TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial显示文摘 | Takayuki Yoshino Nobuyuki Mizunuma Kentaro Yamazaki Tomohiro Nishina Yoshito Komatsu Hideo Baba Akihito Tsuji Kensei Yamaguchi Kei Muro Naotoshi Sugimoto Yasushi Tsuji Toshikazu Moriwaki Taito Esaki Chikuma Hamada Takanori Tanase Atsushi Ohtsu | 2012 | Lancet Oncology2012，，10： | 1 |
| 10 | Multicenter Retrospective Study of 132 Patients with Unresectable Small Bowel Adenocarcinoma Treated with Chemotherapy显示文摘 | Takahiro Tsushima Masataka Taguri Yoshitaka Honma Hideaki Takahashi Shinya Ueda Tomohiro Nishina Hiroki Kawai Shunsuke Kato Mitsukuni Suenaga Fumio Tamura Satoshi Morita Narikazu Boku | 2012 | The Oncologist2012，，9： | 1 |
| 11 | Serum metabolome profiles characterized by patients with hepatocellular carcinoma associated with hepatitis B and C显示文摘AIM: To clarify the characteristics of metabolite profiles in virus-related hepatocellular carcinoma(HCC) patients using serum metabolome analysis. METHODS: The serum levels of low-molecular-weight metabolites in 68 patients with HCC were quantified using capillary electrophoresis chromatography and mass spectrometry. Thirty and 38 of the patients suffered from hepatitis B virus-related HCC(HCC-B) and hepatitis C virus-related HCC(HCC-C), respectively.RESULTS: The main metabolites characteristic of HCC were those associated with glutathione metabolism, notably 13 γ-glutamyl peptides, which are by-products of glutathione induction. Two major profiles, i.e., concentration patterns, of metabolites were identified in HCC patients, and these were classified into two groups: an HCC-B group and an HCC-C group including some of the HCC-B cases. The receiver operating characteristic curve for the multiple logistic regressionmodel discriminating HCC-B from HCC-C incorporating the concentrations of glutamic acid, methionine and γ-glutamyl-glycine-glycine showed a highly significant area under the curve value of 0.94(95%CI: 0.89-1.0, P < 0.0001).CONCLUSION: The serum levels of γ-glutamyl peptides, as well as their concentration patterns, contribute to the development of potential biomarkers for virus-related HCC. The difference in metabolite profiles between HCC-B and HCC-C may reflect the respective metabolic reactions that underlie the different pathogeneses of these two types of HCC. | Takafumi Saito Masahiro Sugimoto Kazuo Okumoto Hiroaki Haga Tomohiro Katsumi Kei Mizuno Taketo Nishina Sonoko Sato Kaori Igarashi Hiroko Maki Masaru Tomita Yoshiyuki Ueno Tomoyoshi Soga | 2016 | World Journal of Gastroenterology2016，22，27： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员